My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 291

    1.

    Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia.

    Chan DC, Watts GF, Barrett PH, Beilin LJ, Redgrave TG, Mori TA.

    Diabetes. 2002 Aug;51(8):2377-86.PMID: 12145148 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.

    Watts GF, Barrett PH, Ji J, Serone AP, Chan DC, Croft KD, Loehrer F, Johnson AG.

    Diabetes. 2003 Mar;52(3):803-11.PMID: 12606523 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Mechanism of action of a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor on apolipoprotein B-100 kinetics in visceral obesity.

    Chan DC, Watts GF, Barrett PH, Mori TA, Beilin LJ, Redgrave TG.

    J Clin Endocrinol Metab. 2002 May;87(5):2283-9.PMID: 11994377 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Factorial study of the effect of n-3 fatty acid supplementation and atorvastatin on the kinetics of HDL apolipoproteins A-I and A-II in men with abdominal obesity.

    Chan DC, Watts GF, Nguyen MN, Barrett PH.

    Am J Clin Nutr. 2006 Jul;84(1):37-43.PMID: 16825679 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma apolipoprotein C-III concentration.

    Chan DC, Watts GF, Redgrave TG, Mori TA, Barrett PH.

    Metabolism. 2002 Aug;51(8):1041-6.PMID: 12145779 [PubMed - indexed for MEDLINE]Related articles

    6.

    Factorial study of the effects of atorvastatin and fish oil on dyslipidaemia in visceral obesity.

    Chan DC, Watts GF, Mori TA, Barrett PH, Beilin LJ, Redgrave TG.

    Eur J Clin Invest. 2002 Jun;32(6):429-36.PMID: 12059988 [PubMed - indexed for MEDLINE]Related articles

    7.

    Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs.

    Burnett JR, Wilcox LJ, Telford DE, Kleinstiver SJ, Barrett PH, Newton RS, Huff MW.

    Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):2589-600.PMID: 9409231 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 studied with a stable isotope technique in men with visceral obesity.

    Riches FM, Watts GF, Naoumova RP, Kelly JM, Croft KD, Thompson GR.

    Int J Obes Relat Metab Disord. 1998 May;22(5):414-23.PMID: 9622338 [PubMed - indexed for MEDLINE]Related articles

    9.

    Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates.

    Forster LF, Stewart G, Bedford D, Stewart JP, Rogers E, Shepherd J, Packard CJ, Caslake MJ.

    Atherosclerosis. 2002 Sep;164(1):129-45.PMID: 12119202 [PubMed - indexed for MEDLINE]Related articles

    10.

    Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes.

    Pontrelli L, Parris W, Adeli K, Cheung RC.

    Metabolism. 2002 Mar;51(3):334-42.PMID: 11887170 [PubMed - indexed for MEDLINE]Related articles

    11.

    Effect of a statin on hepatic apolipoprotein B-100 secretion and plasma campesterol levels in the metabolic syndrome.

    Watts GF, Chan DC, Barrett PH, O'Neill FH, Thompson GR.

    Int J Obes Relat Metab Disord. 2003 Jul;27(7):862-5.PMID: 12821974 [PubMed - indexed for MEDLINE]Related articles

    12.

    The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs.

    Burnett JR, Wilcox LJ, Telford DE, Kleinstiver SJ, Barrett PH, Newton RS, Huff MW.

    Endocrinology. 1999 Nov;140(11):5293-302.PMID: 10537160 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Atorvastatin and fenofibrate have comparable effects on VLDL-apolipoprotein C-III kinetics in men with the metabolic syndrome.

    Chan DC, Watts GF, Ooi EM, Ji J, Johnson AG, Barrett PH.

    Arterioscler Thromb Vasc Biol. 2008 Oct;28(10):1831-7. Epub 2008 Jun 19.PMID: 18566295 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Dose-dependent effects of docosahexaenoic acid supplementation on blood lipids in statin-treated hyperlipidaemic subjects.

    Meyer BJ, Hammervold T, Rustan AC, Howe PR.

    Lipids. 2007 Mar;42(2):109-15. Epub 2007 Feb 8.PMID: 17393216 [PubMed - indexed for MEDLINE]Related articles

    15.

    Physiologic mechanisms of action of lovastatin in nephrotic syndrome.

    Aguilar-Salinas CA, Barrett PH, Kelber J, Delmez J, Schonfeld G.

    J Lipid Res. 1995 Jan;36(1):188-99.PMID: 7706943 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Treatment with atorvastatin ameliorates hepatic very-low-density lipoprotein overproduction in an animal model of insulin resistance, the fructose-fed Syrian golden hamster: evidence that reduced hypertriglyceridemia is accompanied by improved hepatic insulin sensitivity.

    Mangaloglu L, Cheung RC, Van Iderstine SC, Taghibiglou C, Pontrelli L, Adeli K.

    Metabolism. 2002 Apr;51(4):409-18.PMID: 11912545 [PubMed - indexed for MEDLINE]Related articles

    17.

    Early kinetic abnormalities of apoB-containing lipoproteins in insulin-resistant women with abdominal obesity.

    Pont F, Duvillard L, Florentin E, Gambert P, Vergès B.

    Arterioscler Thromb Vasc Biol. 2002 Oct 1;22(10):1726-32.PMID: 12377756 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Postprandial dyslipidemia in men with visceral obesity: an effect of reduced LDL receptor expression?

    Mamo JC, Watts GF, Barrett PH, Smith D, James AP, Pal S.

    Am J Physiol Endocrinol Metab. 2001 Sep;281(3):E626-32.PMID: 11500319 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Variation in Niemann-Pick C1-like 1 gene as a determinant of apolipoprotein B-100 kinetics and response to statin therapy in centrally obese men.

    Chan DC, Watts GF, Wang J, Hegele RA, van Bockxmeer FM, Barrett PH.

    Clin Endocrinol (Oxf). 2008 Jul;69(1):45-51. Epub 2008 Jul 1.PMID: 18031309 [PubMed - indexed for MEDLINE]Related articles

    20.

    Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.

    Guerin M, Egger P, Soudant C, Le Goff W, van Tol A, Dupuis R, Chapman MJ.

    Atherosclerosis. 2002 Aug;163(2):287-96.PMID: 12052475 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity